Point72 Asia Singapore Pte. Ltd. Sells 2,749 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Point72 Asia Singapore Pte. Ltd. reduced its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 23.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,057 shares of the biopharmaceutical company’s stock after selling 2,749 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Theravance Biopharma were worth $77,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TBPH. Gerber LLC bought a new position in shares of Theravance Biopharma in the fourth quarter worth about $112,000. Wellington Management Group LLP increased its holdings in shares of Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company’s stock worth $3,227,000 after purchasing an additional 116,164 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Theravance Biopharma by 16.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,876 shares of the biopharmaceutical company’s stock worth $474,000 after buying an additional 7,509 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Theravance Biopharma by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 49,475 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 3,532 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its stake in Theravance Biopharma by 28.2% during the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 4,990 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Price Performance

Shares of TBPH opened at $8.10 on Friday. The business has a fifty day moving average of $8.32 and a 200 day moving average of $8.82. The company has a market cap of $393.93 million, a PE ratio of -9.42 and a beta of 0.25. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The firm had revenue of $14.26 million during the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same period in the prior year, the company posted ($0.28) EPS. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TBPH has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Leerink Partnrs downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. TD Cowen reduced their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Finally, Leerink Partners downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $15.00 to $10.00 in a report on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.75.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 335,965 shares in the company, valued at $3,023,685. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Eli Samaha bought 999,800 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the purchase, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 6.90% of the stock is currently owned by corporate insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.